2024-09-27 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis

### Company Overview

Eli Lilly and Co is a leading pharmaceutical company known for its innovative drug development and global distribution network.

### Performance Analysis

**1. Return Comparison and Divergence:**

LLY's cumulative return is **895.93%**, significantly outperforming the S&P 500 (VOO) with a cumulative return of **133.29%**. The divergence is **762.64**, placing it at **94.56%** on the historical relative divergence scale, indicating a strong outperformance compared to the benchmark. 

**2. Recent Price Fluctuation:**

* **Closing Price:** 924.56
* **5-day Moving Average:** 918.52
* **20-day Moving Average:** 924.24
* **60-day Moving Average:** 899.02

The stock is currently trading slightly above its 5-day and 20-day moving averages, suggesting potential short-term upside. However, it is below its 60-day moving average, indicating a possible downward trend over the longer term.

**3. Technical Indicators:**

* **RSI:** 55.25 – This suggests that LLY is in a neutral territory, not overbought or oversold.
* **PPO:** -0.21 – A negative PPO indicates a short-term downward momentum.
* **Delta_Previous_Relative_Divergence:** -5.22 – This signifies a recent short-term downtrend in the stock's relative performance.
* **Expected Return:** 6.59% -  This represents the potential maximum annualized return over the next 5 years based on current investment value.

**4. Recent Earnings and Outlook:**

| Date      | EPS   | Revenue          |
|-----------|-------|-------------------|
| 2024-08-08 | 3.29  | 11.30 B$        |
| 2024-04-30 | 2.49  | 8.77 B$         |
| 2023-11-02 | -0.06 | 9.50 B$         |
| 2023-08-08 | 1.96  | 8.31 B$         |
| 2024-08-08 | 1.96  | 8.31 B$         |

The most recent earnings report (2024-08-08) showed EPS of 3.29, surpassing analysts' expectations of 2.85. Revenue also exceeded expectations at 11.30 billion dollars against an estimated 10.99 billion dollars. This positive performance indicates strong growth potential for the company.

**5. News and Recent Issues:**

Based on recent market outlooks, LLY is considered a strong buy by several analysts. FINBOLD highlights the company's strong performance, particularly in its diabetes and immunology divisions.  Recent news reports point to new product launches and continued growth in key markets. 

**6. Summary:**

Eli Lilly and Co exhibits robust performance, exceeding both historical and recent expectations. Its strong earnings, promising pipeline of new products, and favorable market outlook indicate potential for future growth. However, recent price fluctuations and a negative PPO signal some short-term volatility. Overall, LLY remains a strong investment option, especially for investors seeking long-term growth with potentially high returns. 

**Disclaimer:** This analysis is based on publicly available information and does not constitute financial advice. Please consult with a financial advisor before making any investment decisions. 
